[Substitutive therapy with surfactants in premature infants with respiratory distress syndrome].
The main pathogenetic moment of the respiratory distress syndrome (RDS) is recognized to be the lack of alveolar surfactant. Many attempts of substitutive therapy with several kinds of surfactants have been tried (artificial, synthetic, from amniotic fluid, exosurf). After the considerable results obtained in animals, the use of substitutive surfactant proved to be useful also in human newborns with RDS. The authors report the personal data relative to the TA-surfactant (artificial surfactant made of phospholipids + DPPC + protein substances extracted from bovine lung). They analyse first results and, on this ground, they put forward some assumptions in order to obtain a more rational and efficient use.
Liberatore
A
A
Istituto Ospedaliero Provinciale per la Maternità, Milano.
Carrera
G
G
Calciolari
G
G
Coccia
C
C
Coppalini
B
B
Fulconis
F
F
Moro
G
G
Scimone
F
F
Villa
G
G
Minoli
I
I
D000284:Administration, Oral; D004334:Drug Administration Schedule; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D015337:Multicenter Studies as Topic; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D011859:Radiography; D011897:Random Allocation; D012127:Respiratory Distress Syndrome, Newborn / Q000000981:diagnostic imaging / Q000188:drug therapy*
D011663:Pulmonary Surfactants
Terapia sostitutiva con surfattante in prematuri affetti da respiratory distress syndrome.